Literature DB >> 1159842

Spontaneous maturation and differentiation of B16 melanoma cells in culture.

J W Kreider, M E Schmoyer.   

Abstract

B16 melanoma tumors and cultures are composed of cells with different melanin contents and replicative activities. The hypothesis was tested in vitro that these various cells constituted a population in the process of differentiation and maturation. Early cultures were predominantly composed of small, amelanotic cells with high replicative activity. Older cultures contained mostly larger and heavily melanotic cells with little or no replicative activity. Replicative activity, as measured by the uptake of tritiated thymidine, was inversely proportional to cell size and melanin content. Colony-forming ability was impaired if the original cells were melanotic. Tumorigenicity was unaffected except in very old (9-day) cultures. Our results support the concept that malignant melanocytes undergo a sequence of developmental changes which eventuates in the production of mature cells characterized by enlargement, elevated melanin content, and reduced replicative and colony-forming capacity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159842     DOI: 10.1093/jnci/55.3.641

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  In vitro modulation of the metastatic phenotype. I. Analysis of differentiation forms of the B16 melanoma expressing Met-72 determinants and metastatic activity.

Authors:  J H Xiang; A K Kimura
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

2.  msg1, a novel melanocyte-specific gene, encodes a nuclear protein and is associated with pigmentation.

Authors:  T Shioda; M H Fenner; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Limitations of the quantitative cytochemical assay of catechol oxidase in melanoma cells.

Authors:  A C Croce; G Bottiroli; E Prosperi; R Supino; P J Stoward
Journal:  Histochem J       Date:  1988-11

4.  Different growth responses to agents which elevate cAMP in human melanoma cell lines of high and low experimental metastatic capacity.

Authors:  E J Ormerod; I R Hart
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

5.  Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.

Authors:  Yumi Nonomura; Atsushi Otsuka; Chisa Nakashima; Judith A Seidel; Akihiko Kitoh; Teruki Dainichi; Saeko Nakajima; Yu Sawada; Shigeto Matsushita; Megumi Aoki; Tatsuya Takenouchi; Taku Fujimura; Naohito Hatta; Satoshi Koreeda; Satoshi Fukushima; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

6.  Some properties of Bomirski Ab amelanotic melanoma cells, which underwent spontaneous melanization in primary cell culture. Growth kinetics, cell morphology, melanin content and tumorigenicity.

Authors:  A Słomiński
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Tritiated-thymidine-induced increased DNA content and irreversible differentiation in a human melanoma cell line.

Authors:  J W Sheridan; R J Simmons
Journal:  Br J Exp Pathol       Date:  1981-06

8.  Growth response of B16 melanoma to in vivo treatment with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) at the initial stage after tumor transplantation.

Authors:  X H Li; G Paulus; G Atassi; N Buyssens
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

9.  Melanogenesis in genetically determined pigment cell tumors of platyfish and platyfish-swordtail hybrids: correlation between tyrosine activity and degree of malignancy.

Authors:  U Vielkind; W Schlage; F Anders
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-12-15

10.  Cell cultures derived from embryos and melanoma of poeciliid fish.

Authors:  C Kuhn; U Vielkind; F Anders
Journal:  In Vitro       Date:  1979-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.